Location Ogden, Utah, United States Regions Western US Gender Male
LinkedIn View on LinkedIn
Mr. Doman is currently serving as Executive Chairman and Interim CEO after joining Echo's Board of Directors in March 2013.
Mr. Doman brings to Echo Therapeutics over 30 years of executive level, international and domestic management, business development, sales and marketing, product development and strategic planning experience with
specific concentrations in medical devices and pharmaceuticals.
Most recently, Mr. Doman served as President and Chief Executive Officer of publicly-traded DUSA Pharmaceuticals, Inc., which he joined in 2005.
Under his leadership, the company strengthened its IP position, expanded its sales and marketing capabilities and repositioned its products in the marketplace.
In 2012, Mr. Doman completed the successful sale of the company to Sun Pharmaceuticals in a $230 million transaction.
From 2000 to 2004, Mr. Doman served as President of Leach Technology Group, the medical electronic device, design, product development and contract manufacturing services division of Leach Holding Corporation, which was sold to Esterline Technologies in 2004.
He served as President of Device Product Development of West Pharmaceutical Services from 1999 to 2000.
Prior to that, Mr. Doman held marketing and business development positions at the Convatec division of Bristol-Myers Squibb and Critikon, Inc., a Johnson & Johnson company. He earned his Bachelor's degree from Saint Joseph's University.
